ICATA Asthma Mechanistic Study

National Institute of Allergy and Infectious Diseases (NIAID)

Status: Completed

Conditions: Asthma

Treatments: Biological: Omalizumab

Study type: Observational

Funder types: NIH

Identifiers

NCT00377390

DAIT ICAC-09

Details and patient eligibility

About

The purposes of this study are to determine the effects of omalizumab on cells involved in the allergic response, to evaluate predictors of response to omalizumab, and to determine whether response to omalizumab therapy is influenced by the environment. A subset of inner-city children and adolescents currently enrolled in Inner-City Anti-IgE Therapy for Asthma (a clinical trial of omalizumab) will be enrolled in this study.

Full description

Immunoglobulin E (IgE) is important in the development of allergic responses and may determine asthma severity. Omalizumab is a man-made monoclonal antibody that directly blocks the cause of allergic reactions. There are three main objectives to this study. The first is to gain an understanding of how omalizumab affects cells involved in the immune response. The second objective is to determine whether response to omalizumab is influenced by exposure to environmental factors, including allergens and viral infections. The third objective is to determine what clinical markers can be used to determine which patients would most benefit from omalizumab therapy. This study will evaluate the immune and allergic responses of inner-city children with moderate to severe asthma who are receiving omalizumab or placebo as part of a parallel study (Inner-City Anti-IgE Therapy for Asthma, ICAC-08, NCT00377572).

Nasal secretions will be collected from all participants at the beginning of this study, toward the middle of the study, and with each asthma exacerbation requiring a clinical visit. Some participants will participate in either the basophil or T-cell studies and associated procedures. These studies require blood collection at five study visits. Sputum collection will occur at four study visits. Those participants involved in the basophil studies will also undergo skin testing at three study visits.

Enrollment: 224 patients

Sex: All

Ages: 6 to 20 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Currently enrolled in ICATA (ICAC-08, NCT00377572) Clinical Study
• Positive skin test to German cockroach required for participation in the basophil and T-cell studies and associated procedures
• Cockroach insensitive participants will serve as control groups

Trial design

224 participants in 2 patient groups

Cockroach sensitive

Treatment:

Biological: Omalizumab

Control (cockroach insensitive)

Treatment:

Biological: Omalizumab